IOLCP Announces Analyst/Investor Conference Call for Q2 & H1 FY26
IOLCP is organizing a conference call on 13 November 2025 to discuss the financial performance for the second quarter and half year ended 30 September 2025.
The announcement is about scheduling a conference call, which is a routine event and has a low impact on the company's value.
The announcement is a routine notification about a scheduled conference call, providing factual information without expressing any positive or negative sentiment.
* IOL Chemicals and Pharmaceuticals Limited (IOLCP) is organizing an analyst/investor conference call on 13 November 2025 at 12:00 Noon (IST). * The purpose of the call is to discuss the company's financial performance for the second quarter and half year ended 30 September 2025. * Mr. Pardeep Kumar Khanna (Chief Financial Officer), Mr. Abhay Raj Singh (Sr. VP & Company Secretary), Mr. Kushal Kumar Rana (Director Works), and Mr. Rakesh Mahajan (Advisor) will participate in the conference call. * Primary access numbers for the call are +91 22 6280 1550 and +91 22 7115 8378. * International toll-free numbers are also provided for Hong Kong, Singapore, USA, and UK. * Ms. Prachi Ambre from MUFG Intime India Pvt. Ltd. is the contact person for RSVP.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.